<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">J Ophthalmol</journal-id><journal-id journal-id-type="publisher-id">JOPH</journal-id><journal-title-group><journal-title>Journal of Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">2090-004X</issn><issn pub-type="epub">2090-0058</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29862066</article-id><article-id pub-id-type="pmc">5971353</article-id><article-id pub-id-type="doi">10.1155/2018/6543937</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Continuation of Aspirin Therapy before Cataract Surgery with Different Incisions: Safe or Not?</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Qingjian</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Qian</surname><given-names>Yiwen</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yu</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Gaoyuan</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Xian</given-names></name><xref ref-type="aff" rid="I1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0944-8584</contrib-id><name><surname>Wang</surname><given-names>Zhiliang</given-names></name><email>ophwzl@163.com</email><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Department of Ophthalmology, Huashan Hospital, Fudan University, Shanghai, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Victoria W. Y. Wong</p></fn></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>13</day><month>5</month><year>2018</year></pub-date><volume>2018</volume><elocation-id>6543937</elocation-id><history><date date-type="received"><day>6</day><month>2</month><year>2018</year></date><date date-type="rev-recd"><day>20</day><month>3</month><year>2018</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Qingjian Li et al.</copyright-statement><copyright-year>2018</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p> To assess whether to continue aspirin therapy while having uncomplicated phacoemulsification cataract surgery with different incisions. </p></sec><sec><title>Methods</title><p> Consecutive patients having cataract surgery under topical anesthesia with different incisions between May 2016 and August 2017 were followed. 236 eyes of 166 patients on routine aspirin therapy were randomized into 2 groups: continuation group, 112 eyes; discontinuation group, 124 eyes. 121 eyes of 94 patients on no routine anticoagulant therapy were used as the control group. Patients were examined 1 day preoperatively and 1 day and 7 days postoperatively. Intraoperative and postoperative complications were recorded. </p></sec><sec><title>Results</title><p> Statistically, there was no significant difference about postoperative BCVA among three groups. A higher incidence of subconjunctival hemorrhage was shown in the continuation group than in the discontinuation group and the control group (17.0% versus 8.1%, <italic>p</italic>=0.038; 17.0% versus 7.4%, <italic>p</italic>=0.025, resp.). Although corneal edema was greater in clear corneal incision cases than that of scleral tunnel incision cases (22.5% versus 12.0%, <italic>p</italic>=0.009), subconjunctival hemorrhage was greater in scleral tunnel incision cases (14.9% versus 6.6%, <italic>p</italic>=0.011). Subgroup analyses revealed that patients of scleral tunnel incision who continued taking aspirin had a higher incidence of subconjunctival hemorrhage compared with those who discontinued (25.5% versus 10.9%, <italic>p</italic>=0.038), but no same conclusion in clear corneal incision cases (8.8% versus 5.0%, <italic>p</italic>=0.483). </p></sec><sec><title>Conclusions</title><p> The outcomes indicated that phacoemulsification cataract surgery under topical anesthesia could be safely performed without ceasing systemic aspirin therapy. Clear corneal incision could be a better choice in patients treated with aspirin.</p></sec></abstract><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>81670878</award-id></award-group><award-group><funding-source>Science and Technology Commission of Shanghai Municipality</funding-source><award-id>15ZR1425400</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Aspirin has been the cornerstone of preventing thromboembolic complications in patients with cerebrovascular, coronary artery, and peripheral vascular diseases. It is a weak anticoagulant and acts chiefly through the passivation of platelet cyclooxygenase 1 and suppression of thromboxane A2 production. This regimen has significantly reduced risks for morbidity and mortality due to vascular events. The potential benefit of aspirin and the low rate of adverse effects have made aspirin intaking fashionable in the elderly population [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B5" ref-type="bibr">5</xref>]. Cataract surgery is one of the most common surgeries performed in elderly patients [<xref rid="B6" ref-type="bibr">6</xref>]. It is estimated that more than 20% of patients routinely took aspirin before cataract surgery [<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>]. Patients receiving long-term antiplatelet therapy face a significant clinical challenge when they need a cataract surgery. If antiplatelet therapy is suspended, there is a risk for vascular events; however, continuation of aspirin treatment may be closely associated with serious perioperative bleeding complications [<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>]. Hence, there is an issue of whether the risk of thromboembolic events associated with temporarily ceasing antiplatelet treatment before surgery outweighs the advantages of fewer hemorrhagic events. However, at present, there is no clear consistent recommendation in these cases before cataract surgery.</p><p>This prospective randomized study was undertaken to compare the incidence of intraoperative and postoperative complications in patients continuing aspirin therapy and those ceasing it while having phacoemulsification cataract surgery with different incisions.</p></sec><sec id="sec2"><title>2. Methods</title><sec id="sec2.1"><title>2.1. Patients</title><p>This prospective randomized study included consecutive patients who had phacoemulsification cataract surgery under topical anesthesia with different incisions between May 2016 and August 2017 at Huashan Hospital, Fudan University, Shanghai, China. Two hundred thirty-six eyes of 166 patients on routine aspirin therapy were randomized into 2 groups: the continuation group, aspirin continued up to the time of surgery, 112 eyes; the discontinuation group, aspirin discontinued for 3 to 7 days before surgery till 1 day after surgery, 124 eyes. One hundred twenty-one eyes of 94 patients on no routine anticoagulant therapy were used as the control group. The study protocols were accepted by the Institutional Review Board of Huashan Hospital affiliated to Fudan University and performed in accordance with the tenets of the Declaration of Helsinki. Written informed consent was gained from each participant.</p></sec><sec id="sec2.2"><title>2.2. Exclusion Criteria</title><p>Ocular exclusion criteria were previous operation in the same eye, having phacoemulsification cataract surgery combined with other surgeries (e.g., trabeculectomy or pars plana vitrectomy), pupil dilating to be short of 4.0&#x02009;mm, nuclear hardness over grade IV, uncontrolled glaucoma, floppy iris syndrome, and existence of pathological vessels in the operative eye (e.g., iris neovascularization or proliferative diabetic retinopathy). Systemic exclusion criteria were severe renal failure, fasting glucose&#x02009;&#x0003e;&#x02009;9&#x02009;mmol/L, and blood pressure&#x02009;&#x0003e;&#x02009;170/90&#x02009;mmHg. The patients on other kinds of antiplatelets and/or anticoagulants were excluded.</p></sec><sec id="sec2.3"><title>2.3. Data Collection</title><p>All eligible patients had a complete preoperative evaluation including ocular and systemic examination. The ophthalmologic evaluation included slit-lamp biomicroscopy, best-corrected visual acuity (BCVA), intraocular pressure (IOP), and funduscopic examination. The BCVA was converted to the logMAR value, which was used in all statistical analyses. IOP elevation and hypotony were defined as IOPs over 30&#x02009;mmHg and less than 9&#x02009;mmHg, respectively [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. The systemic evaluation included blood, electrocardiogram, and blood pressure. After surgery, the patients were followed up at 1 day and 7 days. All intraoperative and postoperative complications were recorded. Special concern was given to evidence of hemorrhagic complications.</p></sec><sec id="sec2.4"><title>2.4. Surgical Technique</title><p>Three hundred fifty-seven cases of phacoemulsification cataract surgery through different incisions were performed by 1 of 8 skilled surgeons at the same institution. Compound tropicamide eye drop which contained tropicamide (0.5%) and phenylephrine hydrochloride (0.5%) was used as preoperative mydriatic regularly. Topical anesthesia of oxybuprocaine hydrochloride (20&#x02009;ml: 80&#x02009;mg) was used 3 times before cataract surgery. Different incisions were applied according to surgeon's preference. Five surgeons performed through clear corneal incision, while three surgeons preferred scleral tunnel incision. In the scleral tunnel incision cases, after a conjunctival incision at 10:30, cauterization was applied to coagulate conjunctival and episcleral vessels. All surgeons did not know whether the patient was taking aspirin up to the time of surgery or had discontinued the medication some days earlier.</p></sec><sec id="sec2.5"><title>2.5. Statistical Analysis</title><p>SPSS for Windows Version 19.0 (SPSS, Inc., Chicago, IL, USA) was applied for all statistical analysis. Random number table was used for randomization. A two-tailed <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. The Kolmogorov&#x02013;Smirnov test was applied to analyze the distribution of continuous variables. Continuous variables were expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation (SD) for normally distributed data and median (interquartile range (IQR)) for nonnormally distributed data. Categorical variables were expressed as absolute numbers and percentages. Student's <italic>t</italic>-test was applied for normally distributed data, and the Wilcoxon rank sum test was applied for nonnormally distributed data. The chi-square test was used to compare categorical variables between the continuation group and discontinuation group. When small numbers revealed that the chi-square test might be invalid, the Fisher exact test was applied.</p></sec></sec><sec id="sec3"><title>3. Results</title><p>Phacoemulsification cataract surgery under topical anesthesia was performed in 357 eyes of 260 patients. One hundred sixty-six patients took aspirin preoperatively on a daily basis. <xref ref-type="table" rid="tab1"> Table 1</xref> characterizes demographic features. The dosage of aspirin intake was 100&#x02009;mg/day routinely. <xref ref-type="table" rid="tab2"> Table 2</xref> characterizes systemic indication for antiplatelet therapy. The most common systemic clinical indication for aspirin therapy was thromboembolic disease (cerebral infarction, myocardial infarction, venous thrombosis, etc.), which accounted for 70.3% of patients in our study. Other less common indications, which accounted for an additional 10.6%, included atrial fibrillation, mechanical mitral, coronary artery bypass graft, cardiac pacemaker, and dilated cardiomyopathy. But 19.1% of the patients presented no certain systemic clinical indications for aspirin therapy on a daily basis. The three groups were equally distributed in sex, age, BCVA, IOP, types of incision, surgeons, and the proportions of patients having surgery to both eyes. Statistical analysis showed no significant differences between the continuation group and discontinuation group in duration of aspirin intake and systemic indication for antiplatelet therapy.</p><p>
<xref ref-type="table" rid="tab3">Table 3</xref> characterizes the postoperative BCVA and IOP in three groups, and there was no statistic difference among them. One day postoperatively, BCVA was improved from 0.58&#x02009;&#x000b1;&#x02009;0.19 to 0.42&#x02009;&#x000b1;&#x02009;0.39 (in the continuation group), 0.61&#x02009;&#x000b1;0.18 to 0.45&#x02009;&#x000b1;&#x02009;0.39 (in the discontinuation group), and 0.62&#x02009;&#x000b1;0.17 to 0.47&#x02009;&#x000b1;&#x02009;0.45 (in the control group), respectively. And one week postoperatively, BCVA was improved to 0.24&#x02009;&#x000b1;&#x02009;0.19 (in the continuation group), 0.27&#x02009;&#x000b1;&#x02009;0.21 (in the discontinuation group), and 0.27&#x02009;&#x000b1;&#x02009;0.20 (in the control group), respectively.</p><p>
<xref ref-type="table" rid="tab4">Table 4</xref> characterizes the hemorrhagic and nonhemorrhagic complications noted in the three groups. None of the patients suffered from thromboembolic events in our study during the follow-up period. No surgery was canceled or postponed because of bleeding complications. Subconjunctival hemorrhage was the most frequent hemorrhagic complication. There was a higher incidence of subconjunctival hemorrhage in the continuation group than in the discontinuation group and the control group (17.0% versus 8.1%, <italic>p</italic>=0.038; 17.0% versus 7.4%, <italic>p</italic>=0.025, resp.).</p><p>The incidence of subconjunctival hemorrhage was significantly greater in the scleral tunnel incision cases than in the clear corneal incision cases (14.9% versus 6.6%, <italic>p</italic>=0.011). Tables <xref ref-type="table" rid="tab5">5</xref> and <xref ref-type="table" rid="tab6">6</xref> characterize the hemorrhagic and nonhemorrhagic complications in different incision cases. Subgroup analyses revealed that patients of scleral tunnel incision who continued taking aspirin had a higher incidence of subconjunctival hemorrhage compared with those who stopped treatment before surgery (25.5% versus 10.9%, <italic>p</italic>=0.038), but there was no same conclusion in the clear corneal incision cases (8.8% versus 5.0%, <italic>p</italic>=0.483, Fisher's exact test). No patient requested additional clinic visits because of the subconjunctival hemorrhage.</p><p>Corneal edema was the most frequent nonhemorrhagic complication. We found no statistical difference of nonhemorrhagic complication, such as corneal edema, elevated IOP, hypotony, and posterior capsule rupture among the continuation group, discontinuation group, and control group. The incidence of corneal edema was significantly greater in the clear corneal incision cases than in the scleral tunnel incision cases (22.5% versus 12.0%, <italic>p</italic>=0.009), but this complication faded away spontaneously within a week without clinical consequences.</p><p>Another common postoperative nonhemorrhage complication was elevated IOP or hypotony. We found no statistic difference of elevated IOP or hypotony among the continuation group, discontinuation group, and control group. And 78.9% (15/19) of disordered IOP returned to normal within 7 days.</p><p>In the continuation group, one patient had an intraoperative posterior capsule rupture and received secondary implantation of intraocular lens (IOL) without clinical consequences after one month. In the discontinuation group, a patient who had an intraoperative rupture of posterior capsule had instant implantation of IOL and maintained good visual acuity. There were no cases of choroidal/suprachoroidal hemorrhage, vitreous hemorrhage, distorted pupil, retinal detachment, or endophthalmitis.</p></sec><sec id="sec4"><title>4. Discussion</title><p>Antiplatelet therapy is continually encountered in patients desiring cataract surgery. Because of the progressive aging of the population, aspirin users are more likely to be elderly and, therefore, more likely to desire a surgical procedure. The clinical challenge is to conclude whether to continue or to interrupt antithrombotic therapy. It is considered that 10% of all patients receiving oral antiplatelet medications request interrupted treatment for surgery or an invasive procedure each year [<xref rid="B10" ref-type="bibr">10</xref>]. In the past studies, 25.6% of the Canadian Society of Cataract and Refractive Surgery members discontinued aspirin routinely before cataract surgery [<xref rid="B13" ref-type="bibr">13</xref>]. 22.5% of routine aspirin users ceased the medication during the perioperative period of cataract surgery [<xref rid="B8" ref-type="bibr">8</xref>]. To reduce the risk of intraoperative and postoperative hemorrhagic complications, the ophthalmologists preferred to ceasing aspirin 3 to 7 days prior to cataract surgery and interrupt use 1 to 2 days postoperatively, despite the potential risk of thromboembolic events [<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>].</p><p>For decades, whether to stop antiplatelet therapy before cataract surgery remains no decision. Recent studies showed the safety of antiplatelet medications in cataract surgery and no increase in sight-threatening complications, such as severe hemorrhage affecting visual acuity or retinal detachment. [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>]. The American College of Chest Physicians and American Academy of Neurology advised continuous use of antiplatelets before cataract surgery [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>]. The cataract in the Adult Eye Preferred Practice Pattern of the American Academy of Ophthalmology gave a 1- grade recommendation that aspirin should be discontinued perioperatively only if the risk of bleeding outweighed its potential benefit [<xref rid="B20" ref-type="bibr">20</xref>]. Same as these clinical researches, in our experience, there was no statistic difference in postoperative BCVA among the three groups. What's more, except one case of hyphema postoperatively in the continuation group, no case of choroidal/suprachoroidal hemorrhage, vitreous hemorrhage, distorted pupil, retinal detachment, or endophthalmitis happened in patients with aspirin treatment.</p><p>We observed a higher incidence of subconjunctival hemorrhage in patients who continued aspirin therapy compared with those who stopped treatment. This complication was self-limiting without permanent sequelae. Cauterization was applied to coagulate conjunctival and episcleral vessels in the scleral incision cases, but the incidence of subconjunctival hemorrhage was significantly greater in the scleral tunnel incision cases than in the clear corneal incision cases. In 2006, the study by Kumar et al. [<xref rid="B21" ref-type="bibr">21</xref>] showed no difference in incidence of subconjunctival hemorrhage between the aspirin group and control group. But the primary diseases between the two groups were unbalanced and it was relatively a small sample study.</p><p>Results of the subgroup analyses showed that patients of scleral tunnel incision who continued taking aspirin had a higher incidence of subconjunctival hemorrhage compared with those who discontinued for 3 to 7 days before surgery, but there is no same conclusion in the clear corneal incision cases. This meant that aspirin would markedly increase the risk of subconjunctival hemorrhage in scleral tunnel incision cases. No patient requested additional clinic visits because of the subconjunctival hemorrhage. In a study by Kobayashi [<xref rid="B14" ref-type="bibr">14</xref>], patients on antiplatelets and/or anticoagulants continuously showed a higher incidence of subconjunctival hemorrhage compared with the discontinuation group (16.5% versus 10.8%, <italic>p</italic>=0.0309). And the possible reason for bleeding might be the use of subtenon's anesthesia and it was out of date.</p><p>One patient who continued taking aspirin in the clear corneal incision cases had a postoperative hyphema (&#x0003c;2.0&#x02009;mm) that resolved spontaneously in two weeks without affecting visual acuity. The possible explanation was injury of iris vessels during phacoemulsification. The happening of bleeding complication was probably coincidental.</p><p>Corneal edema was the main nonhemorrhagic complication. In our study, there was no significant difference in nonhemorrhagic complications among the continuation group, discontinuation group, and control group. The incidence of corneal edema was significantly greater in the clear corneal incision cases than in the scleral tunnel incision cases, but this complication faded away spontaneously within a week without clinical consequences. The possible explanation for the nonhemorrhagic complication is the excessive manipulation through the incision.</p><p>The major advantage of this study was comparisons of the incidence of intraoperative and postoperative complications among the three groups in different incision cases. The patients of scleral tunnel incision who continued taking aspirin had a higher incidence of subconjunctival hemorrhage compared with those who stopped treatment before surgery, but there was no same conclusion in the clear corneal incision cases. The patients with clear corneal incision had more chance of corneal edema but less subconjunctival hemorrhage compared to patients with scleral tunnel incision. Subconjunctival hemorrhage usually lasts for 2-3 weeks and longer in patients with aspirin treatment. But corneal edema fades away spontaneously within a week without clinical consequences. So, we hold the opinion that clear corneal incision is better than scleral tunnel incision in patients treated with aspirin.</p><p>The patients on other kinds of antiplatelets and/or anticoagulants were excluded from this study. Therefore, we believe that the results represent a true reflection of the hemorrhagic risks associated with the continuation of aspirin uncomplicated by the effect of other medicines.</p><p>This study has limitations. First, because the number of patients was relatively small, the power of analysis was not great enough to discover tiny differences that might have been existent. Second, there were certain indications for use of aspirin that put most routine users at higher risk for bleeding complications than those not on the medication. For example, there was no operative history of percutaneous coronary intervention in the control group. A comparison between the continuation group and discontinuation group is likely to reduce the bias.</p><p>Although patients taking aspirin may be at higher risk for bleeding complications, the practical situation that lots of patients are advised to stop or alter antiplatelet therapy before routine cataract surgery may increase risk of vascular event. If a vascular event did occur, it was much more fearful and resulted in a higher mortality. Furthermore, the technique placing incisions in the avascular clear cornea under topical anesthesia reduces the risk of bleeding complications. A clear consistent recommendation to maintain antiplatelet therapy during phacoemulsification cataract surgery should be instituted by national and international ophthalmic societies.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>The outcomes in our study indicate that phacoemulsification cataract surgery under topical anesthesia could be safely performed without ceasing systemic aspirin therapy. Clear corneal incision could be a better choice in patients treated with aspirin compared with scleral tunnel incision.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by grants from the Natural Science Foundation of China (No. 81670878) and the Science and Technology Commission of Shanghai (15ZR1425400).</p></ack><sec><title>Data Availability</title><p>The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><sec><title>Ethical Approval</title><p>The study protocols were accepted by the Institutional Review Board of Huashan Hospital affiliated to Fudan University and performed in accordance with the tenets of the Declaration of Helsinki.</p></sec><sec><title>Consent</title><p>Written informed consent was gained from each participant.</p></sec><sec><title>Conflicts of Interest</title><p>None of the authors has a financial or proprietary interest in any material or method mentioned.</p></sec><sec><title>Authors' Contributions</title><p>Zhiliang Wang, Qingjian Li, and Yiwen Qian conceived the study design. Zhiliang Wang and Yu Zhang performed the surgeries. Gaoyuan Sun and Xian Zhou analyzed and interpreted the data. Qingjian Li drafted the manuscript. All authors read and approved the final manuscript.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiire</surname><given-names>C. A.</given-names></name><name><surname>Mukherjee</surname><given-names>R.</given-names></name><name><surname>Ruparelia</surname><given-names>N.</given-names></name><name><surname>Keeling</surname><given-names>D.</given-names></name><name><surname>Prendergast</surname><given-names>B.</given-names></name><name><surname>Norris</surname><given-names>J. H.</given-names></name></person-group><article-title>Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery</article-title><year>2014</year><volume>98</volume><issue>10</issue><fpage>1320</fpage><lpage>1324</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2014-304902</pub-id><pub-id pub-id-type="other">2-s2.0-84905091387</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>D. A.</given-names></name><name><surname>Witt</surname><given-names>D. M.</given-names></name><name><surname>Hylek</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum</article-title><year>2008</year><volume>42</volume><issue>7-8</issue><fpage>979</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1345/aph.1l098</pub-id><pub-id pub-id-type="other">2-s2.0-48249098212</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moussouttas</surname><given-names>M.</given-names></name></person-group><article-title>Emerging therapies: clopidogrel and aspirin</article-title><year>2005</year><volume>36</volume><issue>4</issue><fpage>p. 707</fpage><pub-id pub-id-type="doi">10.1161/01.str.0000157951.72934.0b</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>R.</given-names></name><name><surname>Koudstaal</surname><given-names>P.</given-names></name></person-group><article-title>Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack</article-title><year>2004</year><issue>4</issue><fpage>p. CD000187</fpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Segal</surname><given-names>J. B.</given-names></name><name><surname>McNamara</surname><given-names>R. L.</given-names></name><name><surname>Miller</surname><given-names>M. R.</given-names></name><etal/></person-group><article-title>Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs</article-title><year>2000</year><volume>15</volume><issue>1</issue><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1046/j.1525-1497.2000.04329.x</pub-id><pub-id pub-id-type="other">2-s2.0-0033966945</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodge</surname><given-names>W.</given-names></name><name><surname>Horsley</surname><given-names>T.</given-names></name><name><surname>Albiani</surname><given-names>D.</given-names></name><etal/></person-group><article-title>The consequences of waiting for cataract surgery: a systematic review</article-title><year>2007</year><volume>176</volume><issue>9</issue><fpage>1285</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1503/cmaj.060962</pub-id><pub-id pub-id-type="other">2-s2.0-34248157620</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benzimra</surname><given-names>J. D.</given-names></name><name><surname>Johnston</surname><given-names>R. L.</given-names></name><name><surname>Jaycock</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The Cataract National Dataset electronic multicentre audit of 55,567 operations: antiplatelet and anticoagulant medications</article-title><year>2009</year><volume>23</volume><issue>1</issue><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/sj.eye.6703069</pub-id><pub-id pub-id-type="other">2-s2.0-58249119549</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>J.</given-names></name><name><surname>Feldman</surname><given-names>M. A.</given-names></name><name><surname>Bass</surname><given-names>E. B.</given-names></name><etal/></person-group><article-title>Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery</article-title><year>2003</year><volume>110</volume><issue>9</issue><fpage>1784</fpage><lpage>1788</lpage><pub-id pub-id-type="doi">10.1016/s0161-6420(03)00785-1</pub-id><pub-id pub-id-type="other">2-s2.0-0041429414</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grzybowski</surname><given-names>A.</given-names></name><name><surname>Ascaso</surname><given-names>F. J.</given-names></name><name><surname>Kupidura-Majewski</surname><given-names>K.</given-names></name><name><surname>Packer</surname><given-names>M.</given-names></name></person-group><article-title>Continuation of anticoagulant and antiplatelet therapy during phacoemulsification cataract surgery</article-title><year>2015</year><volume>26</volume><issue>1</issue><fpage>28</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1097/icu.0000000000000117</pub-id><pub-id pub-id-type="other">2-s2.0-84916934078</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douketis</surname><given-names>J. D.</given-names></name><name><surname>Berger</surname><given-names>P. B.</given-names></name><name><surname>Dunn</surname><given-names>A. S.</given-names></name><etal/></person-group><article-title>The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)</article-title><year>2008</year><volume>133</volume><issue>6</issue><fpage>299S</fpage><lpage>339S</lpage><pub-id pub-id-type="doi">10.1378/chest.08-0675</pub-id><pub-id pub-id-type="other">2-s2.0-46049099373</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlidis</surname><given-names>M.</given-names></name><name><surname>Korber</surname><given-names>N.</given-names></name><name><surname>Hohn</surname><given-names>F.</given-names></name></person-group><article-title>Surgical and functional results of 27-gauge vitrectomy combined with coaxial 1.8 mm microincision cataract surgery: a consecutive case series</article-title><year>2016</year><volume>36</volume><issue>11</issue><fpage>2093</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1097/iae.0000000000001052</pub-id><pub-id pub-id-type="other">2-s2.0-84964282381</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M.</given-names></name><name><surname>Park</surname><given-names>Y. S.</given-names></name><name><surname>Lee</surname><given-names>D. H.</given-names></name><name><surname>Koh</surname><given-names>H. J.</given-names></name><name><surname>Lee</surname><given-names>S. C.</given-names></name><name><surname>Kim</surname><given-names>S. S.</given-names></name></person-group><article-title>Comparison of surgical outcome of 23-gauge and 25-gauge microincision vitrectomy surgery for management of idiopathic epiretinal membrane in pseudophakic eyes</article-title><year>2015</year><volume>35</volume><issue>10</issue><fpage>2115</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1097/iae.0000000000000598</pub-id><pub-id pub-id-type="other">2-s2.0-84942421642</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong-Tone</surname><given-names>L.</given-names></name><name><surname>Paluck</surname><given-names>E. C.</given-names></name><name><surname>Hart-Mitchell</surname><given-names>R. D.</given-names></name></person-group><article-title>Perioperative use of warfarin and aspirin in cataract surgery by Canadian Society of Cataract and Refractive Surgery members: survey</article-title><year>2005</year><volume>31</volume><issue>5</issue><fpage>991</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1016/j.jcrs.2004.09.058</pub-id><pub-id pub-id-type="other">2-s2.0-20544462429</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>H.</given-names></name></person-group><article-title>Evaluation of the need to discontinue antiplatelet and anticoagulant medications before cataract surgery</article-title><year>2010</year><volume>36</volume><issue>7</issue><fpage>1115</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1016/j.jcrs.2010.01.017</pub-id><pub-id pub-id-type="other">2-s2.0-77953655708</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assia</surname><given-names>E. I.</given-names></name><name><surname>Raskin</surname><given-names>T.</given-names></name><name><surname>Kaiserman</surname><given-names>I.</given-names></name><name><surname>Rotenstreich</surname><given-names>Y.</given-names></name><name><surname>Segev</surname><given-names>F.</given-names></name></person-group><article-title>Effect of aspirin intake on bleeding during cataract surgery</article-title><year>1998</year><volume>24</volume><issue>9</issue><fpage>1243</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1016/s0886-3350(98)80020-5</pub-id><pub-id pub-id-type="other">2-s2.0-0031686678</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barequet</surname><given-names>I. S.</given-names></name><name><surname>Sachs</surname><given-names>D.</given-names></name><name><surname>Shenkman</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Risk assessment of simple phacoemulsification in patients on combined anticoagulant and antiplatelet therapy</article-title><year>2011</year><volume>37</volume><issue>8</issue><fpage>1434</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1016/j.jcrs.2011.02.035</pub-id><pub-id pub-id-type="other">2-s2.0-79960576432</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>K. M.</given-names></name></person-group><article-title>Phacoemulsification and lens implantation in patients treated with aspirin or warfarin</article-title><year>1998</year><volume>24</volume><issue>10</issue><fpage>1361</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1016/s0886-3350(98)80229-0</pub-id><pub-id pub-id-type="other">2-s2.0-0031667167</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>M. J.</given-names></name><name><surname>Gronseth</surname><given-names>G.</given-names></name><name><surname>Anderson</surname><given-names>D. C.</given-names></name><etal/></person-group><article-title>Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology</article-title><year>2013</year><volume>80</volume><issue>22</issue><fpage>2065</fpage><lpage>2069</lpage><pub-id pub-id-type="doi">10.1212/wnl.0b013e318294b32d</pub-id><pub-id pub-id-type="other">2-s2.0-84879493996</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douketis</surname><given-names>J. D.</given-names></name><name><surname>Spyropoulos</surname><given-names>A. C.</given-names></name><name><surname>Spencer</surname><given-names>F. A.</given-names></name><etal/></person-group><article-title>Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines</article-title><year>2012</year><volume>141</volume><issue>4</issue><fpage>e326S</fpage><lpage>e350S</lpage><pub-id pub-id-type="doi">10.1378/chest.11-2298</pub-id><pub-id pub-id-type="other">2-s2.0-84856804836</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>R. J.</given-names></name><name><surname>Braga-Mele</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>S. H.</given-names></name><etal/></person-group><article-title>Cataract in the adult eye preferred practice pattern(R)</article-title><year>2017</year><volume>124</volume><issue>2</issue><fpage>P1</fpage><lpage>P119</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2016.09.027</pub-id><pub-id pub-id-type="other">2-s2.0-85008657145</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>N.</given-names></name><name><surname>Jivan</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>P.</given-names></name><name><surname>McLure</surname><given-names>H.</given-names></name></person-group><article-title>Sub-Tenon&#x02019;s anesthesia with aspirin, warfarin, and clopidogrel</article-title><year>2006</year><volume>32</volume><issue>6</issue><fpage>1022</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.jcrs.2006.02.035</pub-id><pub-id pub-id-type="other">2-s2.0-33745451565</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Continuation group</th><th align="center" rowspan="1" colspan="1">Discontinuation group</th><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients, <italic>n</italic></td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">94</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Eye, <italic>n</italic></td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">124</td><td align="center" rowspan="1" colspan="1">121</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic>n</italic></td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.223<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Male</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">42</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Female</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Age, year</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.193<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" rowspan="1" colspan="1">75.2&#x02009;&#x000b1;&#x02009;8.6</td><td align="center" rowspan="1" colspan="1">76.3&#x02009;&#x000b1;&#x02009;7.3</td><td align="center" rowspan="1" colspan="1">74.5&#x02009;&#x000b1;&#x02009;8.0</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Range</td><td align="center" rowspan="1" colspan="1">50&#x02013;93</td><td align="center" rowspan="1" colspan="1">55&#x02013;90</td><td align="center" rowspan="1" colspan="1">58&#x02013;89</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">BCVA, logMAR</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.165<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" rowspan="1" colspan="1">0.58&#x02009;&#x000b1;&#x02009;0.19</td><td align="center" rowspan="1" colspan="1">0.61&#x02009;&#x000b1;&#x02009;0.18</td><td align="center" rowspan="1" colspan="1">0.62&#x02009;&#x000b1;&#x02009;0.17</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">IOP, mmHg</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.210<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Mean&#x02009;&#x000b1;&#x02009;SD</td><td align="center" rowspan="1" colspan="1">15.9&#x02009;&#x000b1;&#x02009;2.6</td><td align="center" rowspan="1" colspan="1">15.2&#x02009;&#x000b1;&#x02009;2.6</td><td align="center" rowspan="1" colspan="1">15.6&#x02009;&#x000b1;&#x02009;2.9</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Aspirin duration, month</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.119<sup>c</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Median (IQR)</td><td align="center" rowspan="1" colspan="1">60 (24&#x02013;96)</td><td align="center" rowspan="1" colspan="1">60 (36&#x02013;120)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of incision, <italic>n</italic></td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.706<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Corneal incision</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Scleral incision</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr></tbody></table><table-wrap-foot><fn><p>BCVA&#x02009;=&#x02009;best-corrected visual acuity; IOP&#x02009;=&#x02009;intraocular pressure; <sup>a</sup>chi-square test; <sup>b</sup>Student's <italic>t</italic>-test; <sup>C</sup>Wilcoxon rank sum test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Systemic indication for antiplatelet therapy.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Systemic indication for antiplatelet therapy</th><th align="center" colspan="2" rowspan="1">Eyes, <italic>n</italic> (%)</th><th align="center" rowspan="2" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">Continuation group (<italic>n</italic>=112)</th><th align="center" rowspan="1" colspan="1">Discontinuation group (<italic>n</italic>=124)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Thromboembolic disease</td><td align="center" rowspan="1" colspan="1">84 (75.0)</td><td align="center" rowspan="1" colspan="1">82 (66.1)</td><td align="center" rowspan="1" colspan="1">0.136<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">4 (3.6)</td><td align="center" rowspan="1" colspan="1">7 (5.6)</td><td align="center" rowspan="1" colspan="1">0.450<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Mechanical mitral</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">4 (3.2)</td><td align="center" rowspan="1" colspan="1">0.373<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary artery bypass graft</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">3 (2.4)</td><td align="center" rowspan="1" colspan="1">0.624<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiac pacemaker</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">2 (1.6)</td><td align="center" rowspan="1" colspan="1">1.000<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Dilated cardiomyopathy</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">1.000<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Precaution</td><td align="center" rowspan="1" colspan="1">20 (17.8)</td><td align="center" rowspan="1" colspan="1">25 (20.2)</td><td align="center" rowspan="1" colspan="1">0.653<sup>a</sup></td></tr></tbody></table><table-wrap-foot><fn><p>Precaution&#x02009;=&#x02009;patients without certain systemic clinical indication; <sup>a</sup>chi-square test; <sup>d</sup>Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Postoperative BCVA and IOP by group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="center" rowspan="1" colspan="1">Continuation group (<italic>n</italic>=112)</th><th align="center" rowspan="1" colspan="1">Discontinuation group (<italic>n</italic>=124)</th><th align="center" rowspan="1" colspan="1">Control group (<italic>n</italic>=121)</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">One day postoperative</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;BCVA, logMAR</td><td align="center" rowspan="1" colspan="1">0.42&#x02009;&#x000b1;&#x02009;0.39</td><td align="center" rowspan="1" colspan="1">0.45&#x02009;&#x000b1;&#x02009;0.39</td><td align="center" rowspan="1" colspan="1">0.47&#x02009;&#x000b1;&#x02009;0.45</td><td align="center" rowspan="1" colspan="1">0.698<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IOP, mmHg</td><td align="center" rowspan="1" colspan="1">17.5&#x02009;&#x000b1;&#x02009;4.5</td><td align="center" rowspan="1" colspan="1">18.0&#x02009;&#x000b1;&#x02009;5.0</td><td align="center" rowspan="1" colspan="1">17.6&#x02009;&#x000b1;&#x02009;4.9</td><td align="center" rowspan="1" colspan="1">0.729<sup>b</sup></td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">One week postoperative</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;BCVA, logMAR</td><td align="center" rowspan="1" colspan="1">0.24&#x02009;&#x000b1;&#x02009;0.19</td><td align="center" rowspan="1" colspan="1">0.28&#x02009;&#x000b1;&#x02009;0.21</td><td align="center" rowspan="1" colspan="1">0.27&#x02009;&#x000b1;&#x02009;0.20</td><td align="center" rowspan="1" colspan="1">0.425<sup>b</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IOP, mmHg</td><td align="center" rowspan="1" colspan="1">16.2&#x02009;&#x000b1;&#x02009;2.8</td><td align="center" rowspan="1" colspan="1">16.1&#x02009;&#x000b1;&#x02009;3.0</td><td align="center" rowspan="1" colspan="1">15.8&#x02009;&#x000b1;&#x02009;3.0</td><td align="center" rowspan="1" colspan="1">0.531<sup>b</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>b</sup>Student's <italic>t</italic>-test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Incidence of complications by group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Complication</th><th align="center" colspan="3" rowspan="1">Eyes, <italic>n</italic> (%)</th><th align="center" rowspan="2" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">Continuation group (<italic>n</italic>=112)</th><th align="center" rowspan="1" colspan="1">Discontinuation group (<italic>n</italic>=124)</th><th align="center" rowspan="1" colspan="1">Control group (<italic>n</italic>=121)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Subconjunctival hemorrhagic</td><td align="center" rowspan="1" colspan="1">19 (17.0)</td><td align="center" rowspan="1" colspan="1">10 (8.1)</td><td align="center" rowspan="1" colspan="1">9 (7.4)</td><td align="center" rowspan="1" colspan="1">0.032<sup>a</sup><sup>&#x02217;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hyphema</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0.334<sup>d</sup></td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nonhemorrhagic</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Corneal edema</td><td align="center" rowspan="1" colspan="1">21 (18.8)</td><td align="center" rowspan="1" colspan="1">22 (17.7)</td><td align="center" rowspan="1" colspan="1">19 (15.7)</td><td align="center" rowspan="1" colspan="1">0.821<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Posterior capsule rupture</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">1 (0.8)</td><td align="center" rowspan="1" colspan="1">2 (1.7)</td><td align="center" rowspan="1" colspan="1">0.790<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypotony (&#x0003c;9&#x02009;mmHg)</td><td align="center" rowspan="1" colspan="1">1 (0.9)</td><td align="center" rowspan="1" colspan="1">3 (2.4)</td><td align="center" rowspan="1" colspan="1">4 (3.3)</td><td align="center" rowspan="1" colspan="1">0.455<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IOP elevation (&#x0003e;30&#x02009;mmHg)</td><td align="center" rowspan="1" colspan="1">3 (2.7)</td><td align="center" rowspan="1" colspan="1">6 (4.8)</td><td align="center" rowspan="1" colspan="1">2 (1.7)</td><td align="center" rowspan="1" colspan="1">0.338<sup>d</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>
<italic>p</italic> &#x0003c; 0.05; <sup>a</sup>chi-square test; <sup>d</sup>Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Incidence of complications in scleral tunnel incision cases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Complication</th><th align="center" colspan="3" rowspan="1">Eyes, <italic>n</italic> (%)</th><th align="center" rowspan="2" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">Continuation group (<italic>n</italic>=55)</th><th align="center" rowspan="1" colspan="1">Discontinuation group (<italic>n</italic>=64)</th><th align="center" rowspan="1" colspan="1">Control group (<italic>n</italic>=56)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Subconjunctival hemorrhagic</td><td align="center" rowspan="1" colspan="1">14 (25.5)</td><td align="center" rowspan="1" colspan="1">7 (10.9)</td><td align="center" rowspan="1" colspan="1">5 (8.9)</td><td align="center" rowspan="1" colspan="1">0.027<sup>a</sup><sup>&#x02217;</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hyphema</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nonhemorrhagic</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Corneal edema</td><td align="center" rowspan="1" colspan="1">7 (12.7)</td><td align="center" rowspan="1" colspan="1">8 (12.5)</td><td align="center" rowspan="1" colspan="1">6 (10.7)</td><td align="center" rowspan="1" colspan="1">0.937<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Posterior capsule rupture</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">1 (1.6)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0.418<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypotony (&#x0003c;9&#x02009;mmHg)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">2 (3.1)</td><td align="center" rowspan="1" colspan="1">2 (3.6)</td><td align="center" rowspan="1" colspan="1">0.386<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IOP elevation (&#x0003e;30&#x02009;mmHg)</td><td align="center" rowspan="1" colspan="1">1 (1.8)</td><td align="center" rowspan="1" colspan="1">4 (6.2)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0.105<sup>d</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>&#x02217;</sup>
<italic>p</italic> &#x0003c; 0.05; <sup>a</sup>chi-square test; <sup>d</sup>Fisher's exact test.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Incidence of complications in clear corneal incision cases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Complication</th><th align="center" colspan="3" rowspan="1">Eyes, <italic>n</italic> (%)</th><th align="center" rowspan="2" colspan="1">
<italic>p</italic> value</th></tr><tr><th align="center" rowspan="1" colspan="1">Continuation group (<italic>n</italic>=57)</th><th align="center" rowspan="1" colspan="1">Discontinuation group (<italic>n</italic>=60)</th><th align="center" rowspan="1" colspan="1">Control group (<italic>n</italic>=65)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hemorrhagic</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Subconjunctival hemorrhagic</td><td align="center" rowspan="1" colspan="1">5 (8.8)</td><td align="center" rowspan="1" colspan="1">3 (5.0)</td><td align="center" rowspan="1" colspan="1">4 (6.2)</td><td align="center" rowspan="1" colspan="1">0.702<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hyphema</td><td align="center" rowspan="1" colspan="1">1 (1.8)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">0.332<sup>d</sup></td></tr><tr><td align="left" colspan="5" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Nonhemorrhagic</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td><td align="left" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Corneal edema</td><td align="center" rowspan="1" colspan="1">14 (24.6)</td><td align="center" rowspan="1" colspan="1">14 (23.3)</td><td align="center" rowspan="1" colspan="1">13 (20.0)</td><td align="center" rowspan="1" colspan="1">0.821<sup>a</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Posterior capsule rupture</td><td align="center" rowspan="1" colspan="1">1 (1.8)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">2 (3.1)</td><td align="center" rowspan="1" colspan="1">0.401<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Hypotony (&#x0003c;9&#x02009;mmHg)</td><td align="center" rowspan="1" colspan="1">1 (1.8)</td><td align="center" rowspan="1" colspan="1">1 (1.7)</td><td align="center" rowspan="1" colspan="1">2 (3.1)</td><td align="center" rowspan="1" colspan="1">0.833<sup>d</sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;IOP elevation (&#x0003e;30&#x02009;mmHg)</td><td align="center" rowspan="1" colspan="1">2 (3.5)</td><td align="center" rowspan="1" colspan="1">2 (3.3)</td><td align="center" rowspan="1" colspan="1">2 (3.1)</td><td align="center" rowspan="1" colspan="1">0.991<sup>d</sup></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>Chi-square test; <sup>d</sup>Fisher's exact test.</p></fn></table-wrap-foot></table-wrap></floats-group></article>